Repligen Corporation (NASDAQ:RGEN) Shares Bought by XTX Topco Ltd

XTX Topco Ltd boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 34.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,935 shares of the biotechnology company's stock after acquiring an additional 3,295 shares during the quarter. XTX Topco Ltd's holdings in Repligen were worth $1,646,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in RGEN. LPL Financial LLC grew its stake in Repligen by 47.6% in the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after purchasing an additional 10,395 shares in the last quarter. Norges Bank bought a new position in Repligen in the fourth quarter worth approximately $24,034,000. Pictet Asset Management Holding SA grew its stake in Repligen by 14.4% in the fourth quarter. Pictet Asset Management Holding SA now owns 7,879 shares of the biotechnology company's stock worth $1,134,000 after purchasing an additional 992 shares in the last quarter. Westpac Banking Corp grew its stake in Repligen by 17.9% in the fourth quarter. Westpac Banking Corp now owns 21,725 shares of the biotechnology company's stock worth $3,127,000 after purchasing an additional 3,305 shares in the last quarter. Finally, ExodusPoint Capital Management LP lifted its holdings in Repligen by 122.8% during the fourth quarter. ExodusPoint Capital Management LP now owns 213,718 shares of the biotechnology company's stock worth $30,763,000 after buying an additional 117,787 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of analyst reports. Barclays initiated coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. Canaccord Genuity Group lowered their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Stephens upgraded Repligen to an "overweight" rating and set a $160.00 target price for the company in a report on Tuesday, July 22nd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $1.84 during mid-day trading on Friday, hitting $118.91. The stock had a trading volume of 941,488 shares, compared to its average volume of 948,438. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The company has a 50 day moving average of $123.39 and a two-hundred day moving average of $136.49. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The firm has a market cap of $6.68 billion, a PE ratio of -475.62, a PEG ratio of 2.15 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period in the previous year, the company earned $0.40 earnings per share. Repligen's revenue was up 14.8% on a year-over-year basis. Research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.